CTOs on the Move

Magenta Therapeutics

www.magentatx.com

 
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood based diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.magentatx.com
  • 50 Hampshire Street 8th Floor
    Cambridge, MA USA 02139
  • Phone: 857.242.0170

Executives

Name Title Contact Details
David Nichols
Chief Technical Officer Profile

Funding

Magenta Therapeutics raised $48.5M on 11/17/2016
Magenta Therapeutics raised $50M on 05/02/2017
Magenta Therapeutics raised $52M on 04/09/2018
Magenta Therapeutics raised $86.4M on 05/12/2021

Similar Companies

Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company`s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.

Facet Biotech Corporation

Facet Biotech Corporation is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brijen Biotech

Brijen Biotech is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clintech Research

Clintech Research is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevian

Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.